Trial · NCT01548001
Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis
NCT01548001, Phase 4, Unknown, Jiangsu Simcere Pharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis. Trials, record NCT01548001. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01548001
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- NCT number
- NCT01548001
- Status
- Unknown
- Phases
- Phase 4
- Enrollment
- 910 participants, actual
- Lead sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Conditions
- Rheumatoid Arthritis
- Interventions
- Iguratimod, Methotrexate
- First posted
- 2012-03-08
- Last updated
- 2016-02-23
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of patients with ACR 20 response | week 52 | |
| Primary | Change from baseline in modified Total Sharp Score (mTSS) | week 52 | |
| Secondary | Change from baseline in mTSS | week 24 | |
| Secondary | Percentage of patients achieving radiographic non-progression | week 24, week 52 | |
| Secondary | Percentage of patients with ACR 20 response | week 12, week 24, week 40 | |
| Secondary | Percentage of patients with ACR 50 response | week 12, week 24, week 40, week 52 | |
| Secondary | Percentage of patients with ACR 70 response | week 12, week 24, week 40, week 52 | |
| Secondary | Percentage of patients with Simplified Disease Activity Index (SDAI) ≤ 3.3 | week 12, week 24, week 40, week 52 | |
| Secondary | Change from baseline in Health Assessment Questionnaire (HAQ) | week 12, week 24, week 40, week 52 | |
| Secondary | Incidence of adverse events | up to 2 years |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39056160 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01548001
GET https://conductscience.org/api/trials/v1/NCT01548001/registered